Leshmanịasis
| obere ụdị nke | parasitic protozoa infectious disease, vector-borne disease, disease  |
|---|---|
| health specialty | infectious diseases |
| nyocha ahụike | physical examination, ELISEA, polymerase chain reaction, hematology, Giemsa stain |
| drug or therapy used for treatment | itraconazole, Ketoconazole, pentamidine, miltefosine, paromomycin |
| risk factor | erighị ihe na-edozi ahụ́, njem mmadụ, immunosuppression, igbukpọ osisi, ime obodo |
| ICD-9-CM | 085, 085.9 |
| NCI Thesaurus ID | C34767 |
Leshmanịasis nke a na-asụpekwa dịka leshmanịọsis bụ nje nke ihe n'akpata ya bụ [[nje n’eri ihe n’ahụ mmadụ nke leshmanịama nke n'agbasa mgbe ụmụ ahụhụ taara mmadụ..[1] Enwere ụdị atọ nke nje a: Ọnya_Leshmanịasis nke ime ahụ maọbụ ịba ojii.[1] Nke nọ n'elu ahụ n'egosi ọnya, ebe nkeọzọ n'egosi ọnya n'elu ahụ, ọnụ na imi. Nke ịba ojii n'eji ọnya ebido nke n'emecha ghọọ ịba nke n'amị ọbara ma banye na umeji na ihe n'enye aka inwekwu ọbara ma mebie ya.[1][2]
Onwere ụdị karịrị iri abụọ dị iche iche esi ebute nje "Leshmanịa".[1] Ihe nwere ike ime ka mmadụ nweta ya gụnyere ịda ogbenye, erighị ezigbo nri, igbutusi osisi, n'ịga obodo ndị mepere emepe.[1] Enwere ike ime nchọpụta maka ọrịa a site n'iji nkanụzụ eji enyo ihe anya agaghị ahụ.[1] Na mgbakwunye, enwere ike inyoputa ma mmadụ onwere ya site n'ile ọbara onye ahụ.[2]
Enwere ike igbochi leshmanịasis site n'idina na akwa mgbochi emere maka iji zere ihe ịta mmadụ.[1] Ihe ndịọzọ enwere ike ime bụ ịfesa ihe n'egbu ahụhụ n'akụkụ ebe ihe n'akpata ya nọ, n'inye ndị nwere ya ọgwụgwọ ozugbo achọpụtara ya ka ọghara ịgbasa.[1] Naanị mgbe achọpụtara ebe esi nweta nje a, n'ụdị "leshmanịa" ọbụ, na k'esi nweta ya ka a ga-ebido nye ọgwụgwọ.[1] Enwere ike iji ọgwụ liposomal amfoterisin B, mee ihe maka ya,[3] njikọ pentavalent antimonịalsnaparomisin[3] na miltefosine.[4] Maka nke n'egosi ọnya, paromisin,flukonazol,maọbụ pentamidinga-enye nnukwu aka na ya.[5]
Ihe dịka nde 12 ebutela ọrịa a na mba 98[6].[2] Enwere ndekọ ndịọzọ enwere nke bụ n'ihe dịka puku mmadụ 20-50 n'anwụ na ya kwa afọ[2].[1][7] Ihe dịka nde mmadụ 2 na Eshia, Afrịka, Sawụtụ na Sentral Amerịka na ọdịda anyanwụ Urop bụ ebe enwekarịrị nje a.[2][8] Ndị Wọld Helt Ọganaịzeshọn enwetala ọgwụ n'ọnụego dị ala maka iji gwọọ ọrịa a.[2] Enwekwara ike inweta anụmanụ ndị nwere ya n'ime ahụ ha, nke gụnyere nkịtana ahụhụ n'ata ata.[1]
Ebe akpọtụrụ uche
dezie- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Leishmaniasis Fact sheet N°375. World Health Organization (January 2014). Retrieved on 17 February 2014.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Barrett, MP (2012). "Management of trypanosomiasis and leishmaniasis.". British medical bulletin 104: 175–96. DOI:10.1093/bmb/lds031. PMID 23137768.
- ↑ 3.0 3.1 Sundar, S (Jan 2013). "Leishmaniasis: an update of current pharmacotherapy.". Expert opinion on pharmacotherapy 14 (1): 53–63. DOI:10.1517/14656566.2013.755515. PMID 23256501.
- ↑ Dorlo, TP (Nov 2012). "Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.". The Journal of antimicrobial chemotherapy 67 (11): 2576–97. DOI:10.1093/jac/dks275. PMID 22833634.
- ↑ Minodier, P (May 2007). "Cutaneous leishmaniasis treatment.". Travel medicine and infectious disease 5 (3): 150–8. DOI:10.1016/j.tmaid.2006.09.004. PMID 17448941.
- ↑ Leishmaniasis Magnitude of the problem. World Health Organization. Retrieved on 17 February 2014.
- ↑ Lozano, R (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2095–128. DOI:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- ↑ Ejazi, SA (Jan 2013). "Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.". Expert review of anti-infective therapy 11 (1): 79–98. DOI:10.1586/eri.12.148. PMID 23428104.